PHG
KONINKLIJKE PHILIPS NV
$26.11
+0.46%
$25.7B
No data for this timeframe.
Vol
Market Cap$25.7B
Cap SizeLarge Cap
Inst. Holders6 funds
Inst. Value$237.3M
Inst. Activity1 buys / 1 sells
SEC Reports2
Press Releases2
Exchange OTC·Sector X-Ray Apparatus & Tubes & Related Irradiation Apparatus·Inc. P7·CIK 0000313216·Prev Close $25.99
Recent Activity
May 16, 2026
SEC
The Fifth Circuit affirmed the district court's spoliation sanctions and damages award in favor of Philips North America
COURT-RULING — Impact 4/10
May 6, 2026
SEC
Philips reported Q1 2026 EPS of $0.50, a 165.3% beat vs $0.19 consensus, on revenue of EUR 3.9B (+4% comparable sales gr
PRESS-RELEASE — Impact 8/10
Inst.
UBS Group AG — TRIM
332,179 shares ($9.1M)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
118,665 shares ($3.2M)
Jun 4, 2026
other
WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland
<p align="left">June 4, 2026</p>
Jun 2, 2026
Press
Royal Philips announced the exchange ratio for its 2025 dividend: 1 new share per 26.9341 existing shares, based on a VW
Impact 2/10
May 15, 2026
Event
Philips North America v. Image Tech Conslt
Court ruling from Court of Appeals for the Fifth Circuit. Docket: 25-10549
Mar 23, 2026
Press
Royal Philips announced proposed appointments and re-appointments to its Supervisory Board ahead of the 2026 Annual Gene
Impact 3/10
Price Targets
Historical data — last covering-analyst action Feb 2025. No current recommendation available.
$33.54 (Feb 2025)
Current $26.11
Low $29.20
Median $31.00
High $41.00
5 analysts
$29.20
$41.00
Analyst Ratings
6Strong Buy
10Buy
13Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 20, 2025 | UBS | UPGRADE | Neutral → Buy |
| Oct 29, 2024 | Jefferies | UPGRADE | Underperform → Hold |
| May 13, 2024 | Bernstein | UPGRADE | Market Perform → Outperform |
| Apr 30, 2024 | UBS | UPGRADE | Sell → Neutral |
| Apr 30, 2024 | JP Morgan | UPGRADE | Underweight → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.40 ▲ +0.8% | $0.40 — $0.40 | -4% YoY | 1 |
| Next Q | $0.41 ▲ +2.6% | $0.41 — $0.41 | -0% YoY | 1 |
| Current FY | $1.82 | $1.61 — $2.14 | -2% YoY | 4 |
| Next FY | $2.04 | $1.84 — $2.43 | 12% YoY | 4 |
Latest Reports
NEUTRAL
Press
2/10
Royal Philips announced the exchange ratio for its 2025 dividend: 1 new share per 26.9341 existing shares, based on a VW
Jun 2, 2026
BULLISH
COURT-RULING
4/10
The Fifth Circuit affirmed the district court's spoliation sanctions and damages award in favor of Philips North America
May 16, 2026
BULLISH
PRESS-RELEASE
8/10
Philips reported Q1 2026 EPS of $0.50, a 165.3% beat vs $0.19 consensus, on revenue of EUR 3.9B (+4% comparable sales gr
May 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $77.0M | — |
| FMR LLC | $70.5M | TRIM |
| CAUSEWAY CAPITAL MANAGEMENT LLC | $59.5M | — |
| BANK OF AMERICA CORP | $17.6M | TRIM |
| WELLS FARGO & COMPANY/MN | $9.3M | — |
6 institutional holders with $237.3M total value (8,762,321 shares) as of 2025-Q4. Top holders: MORGAN, FMR, CAUSEWAY.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 2,841,880 | $77.0M | 32.4% | — |
| 2 | FMR LLC | 2,605,198 | $70.5M | 29.7% | TRIM -53.1% |
| 3 | CAUSEWAY CAPITAL MANAGEMENT LLC | 2,198,531 | $59.5M | 25.1% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 650,017 | $17.6M | 7.4% | TRIM -41.5% |
| 5 | WELLS FARGO & COMPANY/MN | 343,370 | $9.3M | 3.9% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 123,325 | $3.3M | 1.4% | ADD +58.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 555,645 | 332,179 | -40.2% | $9.1M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 74,811 | 118,665 | +58.6% | $3.2M | 2025-Q3 |
| FMR LLC | TRIM | 5,173,231 | 2,424,738 | -53.1% | $58.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,131,039 | 662,182 | -41.5% | $15.9M | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 123,063 | 326,251 | +165.1% | $8.3M | 2025-Q1 |
| UBS Group AG | ADD | 353,555 | 605,173 | +71.2% | $15.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 218,272 | 123,063 | -43.6% | $3.1M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 55,290 | — | $1.8M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 6.0/10.
Historical analyst distribution (last covering-analyst action Feb 2025): 55% buy across 29 analysts — 6 strong buy, 10 buy, 13 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2025. No current recommendation available.
$33.54 mean target (Feb 2025)
$29.20 Low
$41.00 High
| Metric | Value |
|---|---|
| Current Price | $26.11 |
| Target Low | $29.20 |
| Target Mean | $33.54 |
| Target Median | $31.00 |
| Target High | $41.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.40 | $0.40 | $0.40 | -4.3% | +0.8% | 1↑ 0↓ | $4.3B | -0.6% | 1 |
| Next Q 2026-09-30 |
$0.41 | $0.41 | $0.41 | -0.2% | +2.6% | 1↑ 0↓ | $4.4B | 3.1% | 1 |
| Current FY 2026-12-31 |
$1.82 | $1.61 | $2.14 | -2.2% | -0.1% | 2↑ 2↓ | $18.0B | 0.9% | 4 |
| Next FY 2027-12-31 |
$2.04 | $1.84 | $2.43 | 12.4% | -0.4% | 2↑ 1↓ | $18.8B | 4.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.397 | |
| 7d ago | $0.397 | |
| 30d ago | $0.394 | +0.003 |
| 60d ago | $0.401 | -0.004 |
| 90d ago | $0.408 | -0.010 |
19 analyst firms have rated this stock: 21 upgrades, 15 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 20, 2025 | UBS | UPGRADE | Neutral | Buy |
| Oct 29, 2024 | Jefferies | UPGRADE | Underperform | Hold |
| May 13, 2024 | Bernstein | UPGRADE | Market Perform | Outperform |
| Apr 30, 2024 | UBS | UPGRADE | Sell | Neutral |
| Apr 30, 2024 | JP Morgan | UPGRADE | Underweight | Neutral |
| Jul 25, 2022 | Societe Generale | DOWNGRADE | Buy | Hold |
| Jan 20, 2022 | Jefferies | DOWNGRADE | Buy | Hold |
| Jan 14, 2022 | HSBC | UPGRADE | Hold | Buy |
| Jan 12, 2022 | Citigroup | DOWNGRADE | Buy | Neutral |
| Jul 8, 2021 | Deutsche Bank | DOWNGRADE | Buy | Hold |
| Mar 18, 2021 | JP Morgan | UPGRADE | Neutral | Overweight |
| Jan 13, 2020 | B of A Securities | MAINTAIN | — | Buy |
| Dec 6, 2019 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Sep 13, 2018 | Bernstein | INITIATE | — | Outperform |
| Oct 16, 2017 | Exane BNP Paribas | DOWNGRADE | Outperform | Neutral |
| Jun 21, 2017 | Natixis | DOWNGRADE | Buy | Neutral |
| Dec 12, 2016 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Oct 26, 2016 | HSBC | UPGRADE | Hold | Buy |
| Aug 10, 2016 | UBS | UPGRADE | Neutral | Buy |
| Mar 21, 2016 | Deutsche Bank | UPGRADE | Hold | Buy |
| Feb 16, 2016 | Jefferies | DOWNGRADE | Hold | Underperform |
| Jul 28, 2015 | Barclays | UPGRADE | Underweight | Equal-Weight |
| Jul 28, 2015 | Societe Generale | UPGRADE | Hold | Buy |
| Jan 27, 2015 | Petercam | DOWNGRADE | Buy | Hold |
| Oct 21, 2014 | UBS | DOWNGRADE | Buy | Neutral |
| Sep 29, 2014 | Ingalls & Snyder, LLC | UPGRADE | Hold | Buy |
| Sep 26, 2014 | Morgan Stanley | UPGRADE | Equal-weight | Overweight |
| Apr 23, 2014 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Feb 21, 2014 | Exane BNP Paribas | DOWNGRADE | Neutral | Underperform |
| Feb 5, 2014 | Ingalls & Snyder, LLC | DOWNGRADE | Buy | Hold |
| Oct 28, 2013 | Kepler Cheuvreux | DOWNGRADE | Buy | Hold |
| Oct 21, 2013 | WGZ Bank | UPGRADE | Hold | Buy |
| Jul 23, 2013 | LBBW Research | UPGRADE | Sell | Hold |
| Jul 23, 2013 | JP Morgan | UPGRADE | Neutral | Overweight |
| Jun 6, 2013 | Barclays | UPGRADE | Equal-Weight | Overweight |
| Feb 19, 2013 | Societe Generale | DOWNGRADE | Buy | Hold |
| Jan 23, 2013 | UBS | UPGRADE | Neutral | Buy |
| Jan 9, 2013 | B of A Securities | UPGRADE | Neutral | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 13 | 0 | 0 | 55% | |
| May 1, 2026 | 6 | 11 | 13 | 0 | 0 | 57% | |
| Apr 1, 2026 | 6 | 10 | 14 | 0 | 0 | 53% | |
| Mar 1, 2026 | 6 | 11 | 13 | 0 | 0 | 57% | |
| Feb 1, 2026 | 5 | 10 | 15 | 0 | 0 | 50% | |
| Jan 1, 2026 | 4 | 9 | 15 | 0 | 0 | 46% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland
<p align="left">June 4, 2026</p>
Jun 2, 2026
other
Philips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound
<p>June 2, 2026 </p>
Jun 2, 2026
dividend
Philips announces exchange ratio for 2025 dividend
<p>June 2, 2026<br><br></p>
May 18, 2026
other
Philips highlights advances in imaging and physiology to support complex PCI at EuroPCR 2026
<p>May 18, 2026</p>
May 18, 2026
other
Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm
<p>May 18, 2026</p>
May 15, 2026
Enforcement
Philips North America v. Image Tech Conslt
Court ruling from Court of Appeals for the Fifth Circuit. Docket: 25-10549
May 13, 2026
short_interest
FTD: PHG — 55,624 shares ($1.5M) failed to deliver
Settlement: 20260513, Price: $27.01, FTD Value: $1,502,404.24, KONINKLIJKE PHILIPS N V NEW YO
May 8, 2026
other
Philips shareholders approve all proposals at the AGM 2026
<p>May 8, 2026</p>
May 6, 2026
earnings
Philips delivers strong order intake, comparable sales growth and margin expansion in Q1; 2026 outlook reiterated
<p>May 6, 2026<br><br><br><b>Q1 2026 Group performance</b></p>
Apr 23, 2026
other
Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction
<p>April 23, 2026 </p>
Apr 22, 2026
other
Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning
<p>April 22, 2026</p>
Apr 16, 2026
other
Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications
<p>April 16, 2026</p>
Apr 2, 2026
other
MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member
<p>April 2, 2026</p>
Mar 26, 2026
fda
FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
<p>March 26, 2026</p>
Mar 25, 2026
other
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
<p>March 25, 2026</p>
Mar 24, 2026
other
Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
<p>March 24, 2026</p>